

**Table 2: Summary of Paclitaxel (Oral [oPac+E] and IV) Pharmacokinetic Parameters (PK Analysis Set, n=35)**

Descriptive Statistics	Mean	SD	CV%	Min	Max	Median
<b>Oral Paclitaxel (615 mg/m<sup>2</sup> over 3 consecutive days administered with encequidar)</b>						
<b>AUC<sub>0-t</sub> (ng.h/mL)</b>	4829.4	1375.1	28.5	3082.2	8685.3	4335.3
<b>AUC<sub>0-∞</sub> (ng.h/mL)</b>	5033.5	1401.1	27.8	3289.8	8912.4	4512.8
<b>C<sub>max</sub> (ng/mL)</b>	397.2	157.3	39.6	127.2	838.5	375.6
<b>C<sub>max</sub> (0-24h) (ng/mL)</b>	366.4	156.8	42.8	113.4	838.5	375.6
<b>C<sub>max</sub> (24-48h) (ng/mL)</b>	324.3	147.1	45.4	56.3	737.3	309.5
<b>C<sub>max</sub> (48-72h) (ng/mL)</b>	296.1	127.2	43.0	93.6	559.2	294.2
<b>T<sub>max</sub> (0-24h) (h)</b>	1.4	0.6	42.1	0.8	3.0	1.3
<b>T<sub>max</sub> (24-48h) (h)</b>	25.4	1.1	4.3	24.0	30.5	25.1
<b>T<sub>max</sub> (48-72h) (h)</b>	49.3	0.9	1.8	47.8	53.3	49.3
<b>t<sub>½</sub> (h)</b>	42.89	8.6	20.1	27.8	60.8	41.1
<b>Intravenous Paclitaxel (80 mg/m<sup>2</sup>)</b>						
<b>AUC<sub>0-t</sub> (ng.h/mL)</b>	5431.8	1200.3	22.1	3502.3	8528.4	5265.1
<b>AUC<sub>0-∞</sub> (ng.h/mL)</b>	5595.9	1264.1	22.6	3628.5	8969.6	5395.0
<b>C<sub>max</sub> (ng/mL)</b>	2732.8	629.7	23.0	1720.3	4402.6	2543.0
<b>T<sub>max</sub> (h)</b>	1.0	0.2	22.5	0.7	2.2	1.0
<b>t<sub>½</sub> (h)</b>	26.1	4.3	16.5	16.5	34.5	26.0

Note: The PK Analysis Set includes 35 subjects with complete PK profiles for both oral and IV paclitaxel.

IV = intravenous; Max = maximum; Min = minimum; PK = pharmacokinetic; SD = standard deviation